)
Product Pipeline
Focused on Innovation
CSL is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma protein technology, recombinant protein technology, cell and gene therapy and vaccines technology to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in six Therapeutic Areas - Immunology, Hematology, Respiratory, Cardiovascular and Metabolic, Nephrology and Transplant and Vaccines. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth.
Core Capabilities
as demonstrated in our product pipeline
Phase I
Phase II
Phase III
Registration / Post-Registration
CSL889 Hemopexin (SCD)
Plasma-derived hemopexin for potential treatment of acute Vascular Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) patients.
Anumigilimab (CSL324) Anti-G-CSFR mAb (CAP ARDS)
Recombinant monoclonal antibody against the cytokine granulocyte colony stimulating factor receptor for the potential treatment of community-acquired pneumonia (CAP) Acute respiratory distress syndrome (ARDS).
Trabikibart (CSL311) Anti-Beta Common mAb (Asthma)
Fully human monoclonal antibody inhibiting GM-CSF, IL-3 and IL-5 signalling by neutralising the ß-common receptor for the potential treatment of complex inflammatory diseases such as asthma.
CSL787 Nebulised Ig
Human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non-Cystic Fibrosis Bronchiectasis (NCFB).
C1 Esterase Inhibitor (AIS)
C1-esterase inhibitor (C1-INH) for the treatment of Acute Ischemic Stroke.
CSL040 (Novel Complement Inhibitor)
A recombinant glycoprotein which inhibits the classical, lectin and alternative Complement pathways for the potential treatment of acute indications involving Complement‐mediated tissue damage and inflammation.
Cell-based Influenza (H2N3) Vaccine (SQ009)
For protection against Pandemic Influenza A (H2N3)
sa-mRNA Influenza (H5N1) Vaccine (SQ012 )
For protection against Pandemic Influenza A (H5N1).
sa-mRNA Quadrivalent Influenza Vaccine (ARCT2138)
For protection against four strains of Influenza.
LASN01 Anti-IL-11R mAb (IPF, TED)*
Humanized recombinant monoclonal antibody targeting interleukin-11 (IL-11) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF) and Thyroid Eye Disease (TED).
*Licensed to Lassen Therapeutics.
Anumigilimab (CSL324) Anti-G-CSFR mAb (HS)
Recombinant monoclonal antibody against the cytokine granulocyte colony stimulating factor receptor for the potential treatment of Hidradenitis Suppurativa (HS).
VAMIFEPORT Ferroportin inhibitor (SCD)
Oral ferroportin inhibitor for treatment of beta-thalassemia and Sickle Cell Disease (SCD).
CSL301 α2AP mAb (sPE)
Anti-α2-antiplasmin monoclonal antibody, which is being developed to dissolve thrombi that cause serious conditions such as submassive pulmonary embolism (sPE) and acute ischemic stroke (AIS).
Garadacimab Anti-FXIIa mAb (ILD/IPF)
A humanised anti-FXIIa monoclonal antibody for the potential treatment of Interstitial Lung Diseases (ILD) and Idiopathic Pulmonary Fibrosis (IPF).
Clazakizumab Anti-IL-6 mAb (ESKD)
Humanized recombinant monoclonal antibody targeting interleukin-6 (IL-6) for the potential treatment of end stage kidney disease (ESKD) in patients undergoing dialysis .
Mavrilimumab Anti-GM-CSFR mAb (GCA, COVID)*
Recombinant monoclonal antibody against the granulocyte macrophage colony-stimulating factor receptor as a potential treatment for inflammatory diseases such as Giant Cell Arthritis (GCA & COVID-19).
*Licensed to Kiniksa Pharmaceuticals.
Eblasakimab (CSL334) Anti-IL-13R mAb (AD)*
Monoclonal antibody targeting IL-13Rα1 for the treatment of atopic dermatitis (AD) and asthma.
*Licensed to ASLAN Pharmaceuticals.
HIZENTRA® (DM)
20% subcutaneous immunoglobulin for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).
KCENTRA® 4F-PCC (Trauma)
A 4-factor prothrombin complex concentrate (4F-PCC) for the potential treatment of massive hemorrhage associated with severe traumatic injury.
CSL112 apoA-I (AMI)
Novel apolipoprotein A-I infusion therapy to potentially reduce the risk of major adverse cardiovascular events (MACE) in patients with myocardial infarction (AMI).
SNF472 Calcification inhibitor (CUA-ESKD)
Calcification inhibitor for treatment of calcific uremic arteriolopathy (CUA) in patients with end-stage kidney disease (ESKD).
FILSPARITM(Sparsentan) Dual ETA & AT1 antagonist (FSGS)*
High affinity, dual-acting antagonist of endothelin type A (ETA) & angiotensin type 1 (AT1) for treatment of focal segmental glomerulosclerosis (FSGS).
*Licensed from Travere Therapeutics.
Clazakizumab Anti-IL-6 mAb (ca-AbMR)
Humanized recombinant monoclonal antibody targeting interleukin-6 (IL-6) for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients.
CSL964 Alpha-1 Antitrypsin (Treatment of GvHD)*
Treatment of steroid refractory, acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).
*In collaboration with Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
CSL964 Alpha-1 Antitrypsin (Prevention of GvHD)
Prevention of acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT).
SQ036 (aQIVc) Adjuvanted Cell-based Quadrivalent Influenza Vaccine
For protection against four strains of Seasonal Influenza.
HAEGARDA® (HAE)
Self-administered, subcutaneous C1-esterase inhibitor (human) for routine prophylaxis to prevent HAE attacks.
HIZENTRA® (SCIg) 20% Liquid
20% subcutaneous immunoglobulin.
PRIVIGEN® (IVIg) 10% Liquid
10% intravenous immunoglobulin.
Garadacimab Anti-FXIIa mAb (HAE)
Humanised anti-factor XIIa monoclonal antibody for the potential treatment of Hereditary Angioedema (HAE) by subcutaneous administration.
AFSTYLA® rFVIII (Hem A)
Novel, recombinant factor VIII product for the treatment of adults and children with hemophilia A.
IDELVION® rFIX-FP (Hem B)
Novel, long-acting recombinant factor IX product for the treatment of hemophilia B.
HEMGENIX®
Recombinant adeno-associated viral vector of serotype 5 (AAV5) gene therapy containing the Padua variant of a codon-optimized human FIX complementary deoxyribonucleic acid (AAV5-Padua hFIX) for the treatment of Hemophilia B.
ZEMAIRA® / RESPREEZA® Alpha-1 Antitrypsin
Alpha-1 Proteinase Inhibitor (Human) for treatment of Alpha-1 Antitrypsin (AAT) Deficiency.
FILSPARITM(Sparsentan) Dual ETA & AT1 antagonist (IgAN)*
High affinity, dual-acting antagonist of endothelin type A (ETA) & angiotensin type 1 (AT1) for treatment of immunoglobulin A neuropathy (IgAN).
*Licensed from Travere Therapeutics.
KORSUVA® /KAPRUVIA®KOR agonist (CKD-aP)
Difelikefalin - a kappa-opioid receptor (KOR) agonist for treatment of moderate-to-severe pruritus associated with CKD in adult patients on haemodialysis.
RAYALDEE® Oral ext. release calcifediol (SHPT)*
Orally administered, prolonged-release formulation of calcifediol for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency or deficiency.
*RAYALDEE® is a registered trademark of OPKO Health, Inc.
TAVNEOS® Oral C5a receptor inhibitor (AAV)*
Orally administered, highly potent and selective inhibitor of C5aR1 (complement C5a receptor 1) for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA)-associated vasculitis (AAV).
*TAVNEOS® is a registered trademark of ChemoCentryx Inc.
VELPHORO® Sucroferric oxyhydroxide (Serum P control in CKD)
A non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on haemodialysis or peritoneal dialysis.
VELTASSA® Oral potassium binder (HK)
A non-absorbed, oral potassium binder for the treatment of hyperkalemia.
AUDENZTM Adjuvanted Cell-based Monovalent Influenza A (H5N1) Vaccine
Pre-pandemic, cell-based vaccine combined with CSL Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination), to protect against influenza A (H5N1) - the 'bird-flu' strain.
FOCLIVIA®/AFLUNOV® Adjuvanted Egg-based Influenza A (H5N1) Vaccine
Pre-pandemic, egg-based vaccine combined with CSL Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination), to protect against influenza A (H5N1) - the 'bird-flu' strain.
FLUAD® Trivalent Adjuvanted Egg-based Influenza Vaccine
Seasonal, egg-based trivalent vaccine combined with Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination) to protect against three different strains of influenza.
FLUAD® Quadrivalent Adjuvanted Egg-based Influenza Vaccine
Seasonal, egg-based quadrivalent vaccine, combined with CSL Seqirus' proprietary adjuvant, MF59® (an additive that acts to strengthen the immune response to vaccination) to protect against four different strains of influenza.
FLUCELVAX® Quadrivalent Cell-based Influenza Vaccine
Seasonal cell culture-based, quadrivalent influenza vaccine offering protection against four different strains for use in children 6 months of age and older.
COVID-19 ARCT154 sa-mRNA Vaccine (COVID)
Novel seasonal COVID-19 booster vaccine using self-amplifying platform licensed from Arcturus Therapeutics. The technology offers the potential for higher efficacy and longer duration of protection at lower doses of mRNA.
INJECTAFER® Ferric carboxymaltose (HF-ID)
High dose intravenous iron (ferric carboxymaltose) for the treatment of iron deficiency in heart failure patients.
*Indicates partnered projects